Cite
HARVARD Citation
Hernandez-Ilizaliturri, F. et al. (n.d.). P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL). HemaSphere. pp. 1039-1040. [Online].